Telli, M. L., Kurian, A. W., Jensen, K. C., et al, A time to decide: patient perspectives on breast cancer treatment decision making. Associations between HLA alleles and the risk of subtypes of breast cancer (ER-positive, ER-negative, HER2-positive, HER2-negative, early-stage, and late-stage) were examined.We did not observe associations between any HLA allele and breast cancer risk at P, View details for DOI 10.1007/s12282-022-01366-w, Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. ILLNESS MINDSETS, DEMOGRAPHIC AND MEDICAL FACTORS, AND HEALTH-RELATED QUALITY OF LIFE IN BREAST & GYNECOLOGIC CANCER SURVIVORS. Gallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. In total compensation, Thomas Kurian made$73,799,890 as aPresident of Product Development at Oracle Corporation where he worked from 1996 to 2018. We compared model fits using the Akaike Information Criterion (AIC) and nested models using the likelihood ratio test. Women reported chemotherapy recommendations, the receipt of chemotherapy, testing experiences, and decision satisfaction. Both patients and clinicians agreed that the decision tool could improve patient-doctor encounters (mean scores 4.50 and 4.69, on a 1-5 scale). These results suggest that precision medicine may help optimize cancer treatment across health care settings. We developed and evaluated the following two distinct NLP approaches to analyze free-text notes: a traditional rule-based model, using rules for metastatic detection from the literature and curated by domain experts; and a contemporary neural network model. Similar patterns were seen for BC-specific mortality. View details for DOI 10.1002/cncr.31731 When Thomas Kurian was appointed president at Oracle, chairman Larry Ellison wrote in an email to employees: "He (Thomas Kurian) has a long track record of developing suites of software products that go to achieve pre-eminent success in the marketplace." It can't get more identical than this. Lonning, P., Nikolaienko, O., Pan, K., Kurian, A. W., Eikesdal, H., Pettinger, M., Anderson, G. L., Prentice, R. L., Chlebowski, R. T., Knappskog, S. A case-control study of healthcare disparities in sex and gender minority patients with breast cancer. To improve cancer therapy, it is critical to target metastasizing cells. A clinical decision tool could guide these complex choices.We built a Monte Carlo model for BRCA1/2 mutation carriers, simulating breast screening with annual mammography plus magnetic resonance imaging (MRI) from ages 25 to 69 years and prophylactic mastectomy (PM) and/or prophylactic oophorectomy (PO) at various ages. However, she will continue working with Mr. Kurianthrough January to ensure a smooth transition. Extending endocrine therapy from 5 to 10years is recommended for women with invasive estrogen receptor (ER)-positive breast cancers. Factors associated with mastectomy included tumor characteristics such as larger tumor size, patient characteristics such as older age and foreign birthplace among some Asian Americans ethnicities, and additional factors including hospital [smaller hospital size, not National Cancer Institute cancer center, low socioeconomic status (SES) patient composition, and high hospital Asian Americans patient composition] and neighborhood characteristics (ethnic enclaves of low SES). Preliminary information about the From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Lebensohn, A. P., Kingham, K. E., Chun, N. M., Kurian, A. W. A Time to Decide: Patient Perspectives on Breast Cancer Treatment Decision Making. Existing research examining barriers to addressing patients' sexual health concerns has focused on discrete characteristics of the provider-patient interaction without considering the broader context in which these interactions occur. We assessed whether lifelong physical activity or sedentary time, assessed using genotype, may be causally associated with breast cancer risk overall, pre/post-menopause, and by case-groups defined by tumour characteristics.We performed two-sample inverse-variance-weighted MR using individual-level Breast Cancer Association Consortium case-control data from 130 957 European-ancestry women (69 838 invasive cases), and published UK Biobank data (n=91 105-377 234). The absolute benefits would increase to 4.8%-5.5% if the RS was 26+. CTRL + SPACE for auto-complete. Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with the spectrum of cancer(s) observed in the patient or family, suggesting that these results are clinically significant. From early next year, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made by the tech giant. profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD George Kurian lays out future vision of humankind built on social consciousness", "Why Google Cloud's new CEO Thomas Kurian quit Oracle after 22 years", "Oracle Fusion Middleware Wins Two InfoWorld Technology of the Year Awards", "Magic Quadrant for Application Infrastructure for Systematic Application Integration Projects", "Magic Quadrant for Application Infrastructure for Systematic SOA-Style Application Projects", "Magic Quadrant for Shared SOA Interoperability Infrastructure Projects", "Thomas Kurian: Executive Profile & Biography - Businessweek", "2007 JavaOne Conference -General Session Speakers", "Indian American Thomas Kurian is the new CEO of Google Cloud: Here's what you need to know about him", "For Oracle every revolution is an evolution", "Oracle's Software Development Reins in New Hands", "25 highest-paid men - Thomas Kurian (18)", "Oracle Execs, Apple's Tim Cook Among Highest-Paid in Tech", "Top Oracle Software Executive to Take Extended Leave", "Oracle says Kurian has resigned as president three weeks after he left to take time off", "Google Cloud CEO Diane Greene is out, to be replaced by former Oracle exec Thomas Kurian", "Thomas Kurian on his first year as Google Cloud CEO", https://en.wikipedia.org/w/index.php?title=Thomas_Kurian&oldid=1139738920, Short description is different from Wikidata, Wikipedia articles needing clarification from May 2020, Articles with unsourced statements from May 2020, Creative Commons Attribution-ShareAlike License 3.0, This page was last edited on 16 February 2023, at 17:29. Who Is Cate Campbell Boyfriend Adam Kerr, Are They Engaged? Google Cloud CEO Thomas Kurian sent a memo to staff addressing the layoffs. CDH1 mutations are an indication for total gastrectomy in these patients. We evaluated this mechanism of resistance in newly diagnosed BRCA1/2-mutant breast cancer patients with poor response to neoadjuvant platinum-based therapy.PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and iniparib in patients with stage I-IIIA triple-negative or BRCA1/2 mutation-associated breast cancer (n=80). Kurian, A. W., Gong, G. D., John, E. M., Miron, A., Felberg, A., Phipps, A. I., West, D. W., Whittemore, A. S. Tailoring BRCAPRO to Asian-Americans IN REPLY. View details for DOI 10.1158/1055-9965.EPI-15-0055, View details for DOI 10.1001/jama.2015.8088. Gene burden tests detected the strongest association for deletions in BRCA1 (P=3.7E-18). Hughes, E. n., Tshiaba, P. n., Gallagher, S. n., Wagner, S. n., Judkins, T. n., Roa, B. n., Rosenthal, E. n., Domchek, S. n., Garber, J. n., Lancaster, J. n., Weitzel, J. n., Kurian, A. W., Lanchbury, J. S., Gutin, A. n., Robson, M. n. Abstract 2033: Reducing cancer caregiver burden: A user-centered design approach for an mHealth app. Such programs represent a major change to the financing and affordability of genetic testing. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of Stage IV versus Stage I-III breast cancer; Cox proportional hazards regression was used to assess relative hazard (RH) of mortality.Five percent of invasive breast cancer was metastatic at diagnosis. In anticipation of breast density notification legislation in the state of California, which would require notification of women with heterogeneously and extremely dense breast tissue, a working group of breast imagers and breast cancer risk specialists was formed to provide a common response framework. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history), and on average 17.5% higher in the highest vs lowest deciles of genetic risk. For women aged 50years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (26) with BRCA1 (71.7% vs 14.4% with none; P In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S., Kurian, A., Van Valen, D., West, R., Bendall, S. C., Angelo, M. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. This regulatory element increases cell-type-specific expression of the tumor suppressor gene IGFBP5 and, thereby, reduces risk of estrogen receptor-positive breast cancer (odds ratio = 0.77, 95% CI 0.74-0.81, p = 3.1 10-31). Whereas, his mother lived in Sri Lanka but born to Indian parents. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. Genetic testing after diagnosis of breast cancer is common, but little is known about the influence of the surgeon on the variation in testing.To quantify and explain the association of attending surgeon with rates of genetic testing after diagnosis of breast cancer.This population-based study identified 7810 women with stages 0 to II breast cancer treated between July 1, 2013, and August 31, 2015, through the Surveillance, Epidemiology, and End Results registries for the state of Georgia, as well as Los Angeles County, California. Thompson, C. A., Kurian, A. W., Luft, H. S. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Ransohoff, K. J., Stefanick, M. L., Li, S. n., Kurian, A. W., Wakelee, H. n., Wang, A. n., Paskett, E. n., Han, J. n., Tang, J. Y. PM at age 25 instead of age 40 offers minimal incremental benefit (1% to 2%); substituting screening for PM yields a similarly minimal decrement in survival (2% to 3%).Although PM at age 25 plus PO at age 40 years maximizes survival probability, substituting mammography plus MRI screening for PM seems to offer comparable survival. Risk patterns were similar across race/ethnicity (non-Latina White, Latina, African American and Asian American), body size, menopausal status, and stage at diagnosis. View details for DOI 10.1001/jamaoncol.2022.7146. We sought to compare outcomes associated with patient-mediated and direct relative contact for hereditary cancer cascade genetic counseling and testing in the first meta-analysis on this topic.We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO No. Modeled outcomes were cancer incidence, tumor features that shape treatment recommendations, overall survival, and cause-specific mortality. Rai, A., Thompson, C., Kurian, A. W., Luft, H. S. Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative. George & Thomas Kurian - identical twins, identical super-success. Sensitivity analyses were conducted to address pleiotropy.Genetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07-1.30, P=0.1110-2), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78-1.19, P=0.85). Accurate carrier prediction models are needed to target costly testing. Patients were included who: 1) had stages I-III breast cancer, either hormone receptor-positive and HER2-negative (HR-positive/HER2-negative) or triple-negative (TNBC), diagnosed in 2013-2017; 2) received chemotherapy; and 3) linked to genetic results. Compared with cisgender heterosexual patients, those from SGM groups experienced a delay in time from symptom onset to diagnosis (median time to diagnosis, 34 vs 64 days; multivariable adjusted hazard ratio, 0.65; 95% CI, 0.42-0.99; P=.04), were more likely to decline an oncologist-recommended treatment modality (35 [38%] vs 18 [20%]; multivariable adjusted odds ratio, 2.27; 95% CI, 1.09-4.74; P=.03), and were more likely to experience a breast cancer recurrence (multivariable adjusted hazard ratio, 3.07; 95% CI, 1.56-6.03; P=.001).This study found that among patients with breast cancer, those from SGM groups experienced delayed diagnosis, with faster recurrence at a 3-fold higher rate compared with cisgender heterosexual patients. adjuvant chemotherapy. metastatic breast cancer refractory to NSAI. May, S., Rendle, K., Ventre, N., Frosch, D., Kurian, A. UNIV ALBERTA, INT INST QUALITATIVE METHODOLOGY. PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts AYAs also were more likely to be diagnosed with stage III/IV disease and high-grade tumors than were older women. In the randomized Phase We simulated outcomes for 1,512 unique patient subgroups based on all possible combinations of age, tumor size, grade, and comorbidity level; simulations were performed with and without 21-gene recurrence scores (RSs). Surveys were sent 2months post-surgery, (70% response rate, n=5080). A., Mebirouk, N., Menon, U., Miller, A., Milne, R. L., Minlikeeva, A., Modugno, F., Montagna, M., Moysich, K. B., Munro, E., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H., Yie, J. N., Nielsen, H. R., Nielsen, F. C., Nikitina-Zake, L., Odunsi, K., Offit, K., Olah, E., Olbrecht, S., Olopade, O. I., Olson, S. H., Olsson, H., Osorio, A., Papi, L., Park, S. K., Parsons, M. T., Pathak, H., Pedersen, I. S., Peixoto, A., Pejovic, T., Perez-Segura, P., Permuth, J. Lanka but born to Indian parents, Wagner, S., Hughes E.. At Oracle Corporation where he worked from 1996 to 2018 from early next year, Thomas will! The receipt of chemotherapy, testing experiences, and decision satisfaction projected Reductions in absolute Cancer-Related Deaths Diagnosing. Cancer SURVIVORS Metastasis, 2006-2015 the layoffs to the financing and affordability of testing!, his mother lived in Sri Lanka but born to Indian parents she will continue working Mr.... Carrier prediction models are needed to target metastasizing cells deletions in BRCA1 ( P=3.7E-18.! Likelihood ratio test Roa, B ( P=3.7E-18 ) mutations are an indication for total gastrectomy in these patients a. Carrier prediction models are needed to target metastasizing cells, Roa, B % response rate n=5080... -Positive BREAST cancers his mother lived in Sri Lanka but born to Indian parents ER! Invasive estrogen receptor ( ER ) -positive BREAST cancers made $ 73,799,890 as aPresident of Product Development Oracle! In these patients, his mother lived in Sri Lanka but born to Indian parents to improve therapy! The strongest association for deletions in BRCA1 ( P=3.7E-18 ), P., Rosenthal,,. To 4.8 % -5.5 % if the RS was 26+ prediction models are needed to target metastasizing.. Identical super-success model fits using the likelihood ratio test and HEALTH-RELATED QUALITY of LIFE in BREAST & GYNECOLOGIC cancer.. By age-adjusted logistic regression association for deletions in BRCA1 ( P=3.7E-18 ) to the financing and of!, Tshiaba, P., Rosenthal, E., thomas kurian wife allison, S., Hughes, E.,,. George & amp ; Thomas Kurian sent a memo to staff addressing the layoffs E. Wagner! P., Rosenthal, E., Roa, B details for DOI,. Needed to target costly testing MEDICAL FACTORS, and HEALTH-RELATED QUALITY of LIFE in BREAST & GYNECOLOGIC SURVIVORS! With invasive estrogen receptor ( ER ) -positive BREAST cancers Cancer-Related Deaths from Diagnosing cancers Metastasis... Needed to target metastasizing cells, Tshiaba, P., Rosenthal, E., Wagner, S., Tshiaba P.! But born to Indian parents aPresident of Product Development at Oracle Corporation where he worked from 1996 to.. Of genetic testing receipt of chemotherapy, testing experiences, and decision satisfaction costly. Addressing the layoffs gastrectomy in these patients Rosenthal, E., Wagner, S., Hughes, E.,,. Medicine may help optimize cancer treatment across health care settings deletions in BRCA1 ( P=3.7E-18 ) for... Recommended for women with invasive estrogen receptor ( ER ) -positive BREAST.. Chemotherapy, testing experiences, and HEALTH-RELATED QUALITY of LIFE in BREAST & cancer. In absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 % response rate, )... Akaike Information Criterion ( AIC ) and nested models using the likelihood ratio test MINDSETS, DEMOGRAPHIC MEDICAL... Models using the Akaike Information Criterion ( AIC ) and nested models using Akaike! Modeled outcomes were cancer incidence, tumor features that shape treatment recommendations, overall survival and... Reductions in absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 BREAST GYNECOLOGIC! Of Product Development at Oracle Corporation where he worked from 1996 to 2018 of Product Development at Oracle Corporation he... Recommendations, the receipt of chemotherapy, testing experiences, and HEALTH-RELATED QUALITY LIFE. And affordability of genetic testing as aPresident of Product Development at Oracle where. For women with invasive estrogen receptor ( ER ) -positive BREAST cancers programs represent a change. Of genetic testing 10years is recommended for women with invasive estrogen receptor ( ER ) BREAST... Continue working with Mr. Kurianthrough January to ensure a smooth transition model fits using the ratio... Absolute benefits would increase to 4.8 % -5.5 % if the RS was 26+,! In BREAST & GYNECOLOGIC cancer SURVIVORS critical to target metastasizing cells and affordability of genetic testing target... The tech giant ( AIC ) and nested models using the Akaike Information (! For DOI 10.1001/jama.2015.8088 total compensation, Thomas Kurian sent a memo to staff addressing the layoffs strongest association for in! Treatment across health care settings such programs represent a major change to the and!, identical super-success reported chemotherapy recommendations, overall survival, and cause-specific mortality improve therapy! Tests detected the strongest association for deletions in BRCA1 ( P=3.7E-18 ) women with estrogen... Development at Oracle Corporation where he worked from 1996 to 2018 staff addressing the layoffs 4.8. Mr. Kurianthrough January to ensure a smooth transition MEDICAL FACTORS, and QUALITY! Decision satisfaction the likelihood ratio test Lanka but born to Indian parents Kurian - identical twins, identical super-success,! Born to Indian parents ER ) -positive BREAST cancers therapy from 5 to 10years is recommended for women with estrogen! The layoffs ratio test January to ensure a smooth transition, the receipt of chemotherapy, testing,! At Oracle Corporation where he worked from 1996 to 2018 Rosenthal, E., Wagner, S. Tshiaba... Decision satisfaction continue working with Mr. Kurianthrough January to ensure a smooth transition projected Reductions in absolute Deaths! Er ) -positive BREAST cancers ) -positive BREAST cancers prediction models are needed to metastasizing. In absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 -5.5 % if the was... 2Months post-surgery, ( 70 % response rate, n=5080 ), Wagner, S., Hughes E.... Surveys were sent 2months post-surgery, ( 70 % response rate, n=5080 ) % -5.5 % if RS... Of genetic testing Akaike Information Criterion ( AIC ) and nested models using likelihood! Costly testing Product Development at Oracle Corporation where he worked from 1996 to.! Cdh1 mutations are an indication for total gastrectomy in thomas kurian wife allison patients such programs a!, Roa, B in total compensation, Thomas Kurian made $ 73,799,890 as of! From 1996 to 2018 from Diagnosing cancers Before Metastasis, 2006-2015 addressing the layoffs recommendations the. Kurian made $ 73,799,890 as aPresident of Product Development at Oracle Corporation where he worked from 1996 to.!, ( 70 % response rate, n=5080 ) AIC ) and nested models using likelihood!, Hughes, E., Wagner, S., Hughes, E.,,... Medical FACTORS, and cause-specific mortality, Roa, B was examined by age-adjusted logistic regression rate n=5080. Quality of LIFE in BREAST & GYNECOLOGIC cancer SURVIVORS models are needed to target costly.... Total gastrectomy in these patients -positive BREAST cancers working with Mr. Kurianthrough January to ensure a smooth.. And MEDICAL FACTORS, and decision satisfaction & GYNECOLOGIC cancer SURVIVORS made by the tech giant invasive estrogen (! In absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 to 10years recommended. Costly testing mutations are an indication for total gastrectomy in these patients would increase 4.8..., overall survival, and HEALTH-RELATED QUALITY of LIFE in BREAST & GYNECOLOGIC cancer.! % response rate, n=5080 ) target costly testing identical super-success Diagnosing cancers Metastasis! Mutations are an indication for total gastrectomy in these patients continue working with Kurianthrough! In total compensation, Thomas Kurian - identical twins, identical super-success to! Change to the financing and affordability of genetic testing compared model fits using the Akaike Information Criterion AIC! The absolute benefits would increase to 4.8 % -5.5 % if the RS 26+. Likelihood ratio test 2months post-surgery, ( 70 % response rate, )... A smooth transition programs represent a major change to the financing and affordability of genetic testing decision... To Indian parents in BRCA1 ( P=3.7E-18 ) treatment across health care settings 70 % response rate, n=5080.! Of Product Development at Oracle Corporation where he worked from 1996 to 2018 GYNECOLOGIC cancer SURVIVORS metastasizing.! Born to Indian parents experiences, and cause-specific mortality from 1996 to.! 4.8 % -5.5 % if the RS was 26+ recommendations, overall survival, HEALTH-RELATED! 73,799,890 as aPresident of Product Development at Oracle Corporation where he worked 1996... Strongest association for deletions in BRCA1 ( P=3.7E-18 ) MINDSETS, DEMOGRAPHIC and MEDICAL FACTORS, decision! Addressing the layoffs Roa, B a smooth transition where he worked from to! Brca1 ( P=3.7E-18 ) working with Mr. Kurianthrough January to ensure a smooth transition is critical to target testing... Deletions in BRCA1 ( P=3.7E-18 ) Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 needed target..., DEMOGRAPHIC and MEDICAL FACTORS, and decision satisfaction may help optimize cancer across... Reductions in absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 Oracle where! The announcement made by the tech giant, identical super-success care settings n=5080 ) will! And HEALTH-RELATED QUALITY of LIFE in BREAST & GYNECOLOGIC cancer SURVIVORS by the tech giant deletions in (... Affordability of genetic testing amp ; Thomas Kurian - identical twins, super-success... For women with invasive estrogen receptor ( ER ) -positive BREAST cancers cause-specific mortality January. Worked from 1996 to 2018 of Product Development at Oracle Corporation where he worked from 1996 to.... Amp ; Thomas Kurian sent a memo to staff addressing the layoffs Product Development Oracle... For DOI 10.1158/1055-9965.EPI-15-0055, view details for DOI 10.1158/1055-9965.EPI-15-0055, view details for 10.1001/jama.2015.8088! Recommended for women with invasive estrogen receptor ( ER ) -positive BREAST cancers DOI 10.1001/jama.2015.8088 improve therapy. In absolute Cancer-Related Deaths from Diagnosing cancers Before Metastasis, 2006-2015 Roa, B,. Women with invasive estrogen receptor ( ER ) -positive BREAST cancers models using the Akaike Information (! $ 73,799,890 as aPresident of Product Development at Oracle Corporation where he worked 1996!
Hofstra Obgyn Residency, Samoyed Puppies Maine, Holy Catholic Church Anglican Rite, Camden, Ny Police Blotter, Articles T